Stay updated on Safety & Efficacy of Dupilumab in Young Children Clinical Trial
Sign up to get notified when there's something new on the Safety & Efficacy of Dupilumab in Young Children Clinical Trial page.

Latest updates to the Safety & Efficacy of Dupilumab in Young Children Clinical Trial page
- Check7 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check14 days agoChange DetectedA site-wide banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.” The clinical trial information itself is unchanged.SummaryDifference1%

- Check21 days agoChange DetectedThe ClinicalTrials.gov study page remains inaccessible with a 403 Forbidden error. The site revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check28 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1, while the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check49 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, indicating restricted access to the study details.SummaryDifference21%

- Check70 days agoChange DetectedRevision tag on the page was updated to v3.6.6, replacing the previous v3.6.5. This represents a minor version update of the page metadata rather than a substantive content change.SummaryDifference0.0%

Stay in the know with updates to Safety & Efficacy of Dupilumab in Young Children Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety & Efficacy of Dupilumab in Young Children Clinical Trial page.